Unravel Biosciences, Inc. (referred to as "Unravel") has unveiled a pioneering initiative known as rareSHIFT™, aimed at expediting patient-centric drug discovery and translation with unmatched speed.

Neal I. Muni, M.D., MSPH, Chief Medical Officer at Unravel, highlighted the significance of their drug discovery platform and its pivotal role in advancing novel assets. He stated, "Unravel has developed a highly innovative and efficient drug discovery platform that serves as the engine for our pipeline of novel assets. With the increased urgency expressed by patients, caregivers and their physicians to accelerate the identification of treatments for high unmet need, complex disorders, we are expanding our mission by providing foundation and industry partners with access to our capabilities. We believe that applying our rapid prototyping process with partners will result in a major shift in how highly effective treatment options are identified."

rareSHIFT™ extends partners the opportunity to utilize Unravel's comprehensive suite of cutting-edge discovery and development capabilities, meticulously designed to create a streamlined pathway to clinical application. This initiative involves the generation of patient RNAseq data through at-home collection, enabling the stratification of patient populations. Additionally, it utilizes BioNAV™, an AI network model of human health, which possesses an in-depth understanding of the actual activity of over 40,000 compounds to predict therapeutic targets and drug candidates based on patients' RNA signatures. Another key component is SquishyWare™, a resource for on-demand CRISPR-engineered in vivo models of genetic disorders, enabling swift screening using clinically-relevant metrics from the outset. The integrated drug prototyping process employs existing drugs to mitigate risks associated with novel targets and repurposing opportunities, all while facilitating the development of even more effective novel therapeutics.

Dr. Vinodh Narayanan. M.D., a pediatric neurologist at Arizona Pediatric Neurology and Neurogenetics Associates, emphasized the ongoing need for discovering small molecule treatments for genetic neurological disorders. He highlighted the importance of rareSHIFT™ in reducing the time taken from gene discovery to FDA approval for a compound.

Kasey Edwards, CureAP4 Foundation Co-Founder, and Community Coordinator, expressed the immense value of initiatives like rareSHIFT™ for individuals and families affected by rare diseases. She emphasized that rare disease diagnoses can bring profound fear into the lives of those affected but the potential for rapidly discovering effective treatments offers hope and a reason to smile.